In an article published in the peer-reviewed journal Environmental Heath Perspectives (EHP) on October 16, 2019, Helene Serra and co-authors from the French Agency for Food, Environmental and Occupational Health Safety (ANSES) completed a systematic review to identify adverse effects and endocrine activities of bisphenol B (BPB; CAS 77-40-7) in animal models and in vitro mechanistic studies. The results in existing published literature were grouped by modality, and a weight-of-evidence approach was used to establish biologically plausible links to them. The review led to the analysis of 36 published articles, including 3 sub-chronic studies reporting effects on reproductive function as well as 28-day and 48-week studies showing changes to spermatogenesis, alteration of sperm parameters, and weight loss of testis, epididymis, and seminal vessels. A 21-day study on zebrafish showed exposed fish had lower egg production, hatching rate, and viability. Both in vitro and in vivo studies found that BPB decreases testosterone production and exerts “an estrogenic-like activity similar to or greater than BPA’s” (bisphenol A).
The article concludes that “the available in vivo, ex vivo, and in vitro data, although limited, coherently indicates that BPB meets the WHO definition of an endocrine disrupting chemical currently used in a regulatory context.” In August 2019, France notified the European Chemicals Agency (ECHA) of its intention to propose BPB to be listed as a substance of very high concern (SVHC) under REACH.
Serra H., et al. (2019). “Evidence for Bisphenol B Endocrine Properties: Scientific and Regulatory Perspectives.” Environmental Health Perspectives; 127
Andrew Turley (October 17, 2019). “Anses review concludes bisphenol B is endocrine disruptor.” Chemical Watch